Wall Street brokerages predict that PDS Biotechnology Co. (NASDAQ:PDSB – Get Rating) will announce earnings per share (EPS) of ($0.24) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for PDS Biotechnology’s earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.25). PDS Biotechnology reported earnings per share of ($0.14) during the same quarter last year, which would suggest a negative year-over-year growth rate of 71.4%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that PDS Biotechnology will report full-year earnings of ($0.98) per share for the current year, with EPS estimates ranging from ($1.09) to ($0.89). For the next year, analysts anticipate that the business will post earnings of ($0.30) per share, with EPS estimates ranging from ($0.69) to $0.09. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover PDS Biotechnology.
PDS Biotechnology (NASDAQ:PDSB – Get Rating) last announced its quarterly earnings data on Thursday, March 31st. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.02. During the same period in the previous year, the business posted ($0.16) earnings per share.
PDS Biotechnology stock traded down $0.09 during midday trading on Tuesday, hitting $5.60. 180,276 shares of the company’s stock were exchanged, compared to its average volume of 334,638. The stock has a 50-day moving average price of $6.10 and a two-hundred day moving average price of $8.57. PDS Biotechnology has a 52-week low of $4.10 and a 52-week high of $17.85.
Several institutional investors have recently made changes to their positions in PDSB. Amussen Hunsaker Associates LLC boosted its position in shares of PDS Biotechnology by 5.9% during the 3rd quarter. Amussen Hunsaker Associates LLC now owns 26,739 shares of the company’s stock valued at $398,000 after acquiring an additional 1,500 shares during the last quarter. BlackRock Inc. increased its holdings in PDS Biotechnology by 0.5% in the 4th quarter. BlackRock Inc. now owns 431,405 shares of the company’s stock valued at $3,495,000 after purchasing an additional 2,227 shares during the last quarter. Northern Trust Corp raised its position in PDS Biotechnology by 6.3% in the fourth quarter. Northern Trust Corp now owns 41,820 shares of the company’s stock valued at $339,000 after purchasing an additional 2,466 shares during the period. UBS Group AG acquired a new position in PDS Biotechnology during the third quarter worth $44,000. Finally, Bank of America Corp DE boosted its position in shares of PDS Biotechnology by 7,093.1% during the fourth quarter. Bank of America Corp DE now owns 4,172 shares of the company’s stock worth $34,000 after buying an additional 4,114 shares during the period. 23.91% of the stock is owned by hedge funds and other institutional investors.
PDS Biotechnology Company Profile (Get Rating)
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection.
- Get a free copy of the StockNews.com research report on PDS Biotechnology (PDSB)
- Greenbrier Companies Stock has Green in its Future
- Insiders Are Selling Palo Alto Networks
- Tilray Stock Has Better Days Ahead
- 3 Bank Stocks That Are Ready to Handle Whatever the Fed Throws at Them
- Headwinds Mount For Carmax, Don’t Count On Higher Share Prices
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.